ProCE Banner Activity

Antibody–Drug Conjugates in Lung Cancer

Slideset Download
Download these slides from a live symposium to learn more about targeting HER2, HER3, and TROP2 with antibody-drug conjugates in non-small cell lung cancer.

Released: April 08, 2022

Expiration: April 07, 2023

Share

Faculty

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has received consultant/advisor/speaker fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Certis, Lilly, Genentech, Illumina, Merck, Pfizer, Rakuten, and Tempus and research funds paid to his institution from Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Lilly, Fate Therapeutics, Iovance, Merck, Pfizer, Roche/Genentech, and SQZ Biotechnologies.